Patents by Inventor Graziella I. Shevlin
Graziella I. Shevlin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230119470Abstract: Provided herein are Heteroaryl Compounds having the following structure: wherein R1-R4 are as defined herein, compositions comprising an effective amount of a Heteroaryl Compound and methods for treating or preventing cancer, inflammatory conditions, immunological conditions, neurodegenerative diseases, diabetes, obesity, neurological disorders, age-related diseases, or cardiovascular conditions, comprising administering an effective amount of a Heteroaryl Compound to a patient in need thereof.Type: ApplicationFiled: February 25, 2022Publication date: April 20, 2023Inventors: Jan ELSNER, Kimberly E. Fultz, Roy L. HARRIS, III, Branden Gingsee LEE, Loui Thomas Madakamutil, Deborah S. Mortensen, Rama Krishna Narla, Garrick K. PACKARD, Patrick PAPA, Jason PARNES, Sophie Perrin-Ninkovic, Jennifer RIGGS, Sabita SANKAR, John J. Sapienza, Graziella I. Shevlin, Lida Tehrani, Weiming XU, Jingjing ZHAO
-
Patent number: 11292796Abstract: Provided herein are Heteroaryl Compounds having the following structure: wherein R1-R4 are as defined herein, compositions comprising an effective amount of a Heteroaryl Compound and methods for treating or preventing cancer, inflammatory conditions, immunological conditions, neurodegenerative diseases, diabetes, obesity, neurological disorders, age-related diseases, or cardiovascular conditions, comprising administering an effective amount of a Heteroaryl Compound to a patient in need thereof. Further provided herein are methods for preparing a compound of formula (I), the method comprising contacting a compound of formula (III) with a compound of the following formula: R1-Y, in a solvent, in the presence of a palladium catalyst, wherein said contacting occurs in the presence of a base, wherein R1-R4, Y, the palladium catalyst and the base are as defined herein.Type: GrantFiled: May 4, 2020Date of Patent: April 5, 2022Assignee: Signal Pharmaceuticals, LLCInventors: Jan Elsner, Roy L. Harris, Branden Gingsee Lee, Deborah Mortensen, Garrick K. Packard, Patrick Papa, Jason Parnes, Sophie Perrin-Ninkovic, Jennifer Riggs, John Sapienza, Graziella I. Shevlin, Lida Tehrani, Jingjing Zhao
-
Publication number: 20200262840Abstract: Provided herein are Heteroaryl Compounds having the following structure: wherein R1-R4 are as defined herein, compositions comprising an effective amount of a Heteroaryl Compound and methods for treating or preventing cancer, inflammatory conditions, immunological conditions, neurodegenerative diseases, diabetes, obesity, neurological disorders, age-related diseases, or cardiovascular conditions, comprising administering an effective amount of a Heteroaryl Compound to a patient in need thereof.Type: ApplicationFiled: May 4, 2020Publication date: August 20, 2020Inventors: Jan ELSNER, Roy L. HARRIS, Branden Gingsee LEE, Deborah MORTENSEN, Garrick K. PACKARD, Patrick PAPA, Jason PARNES, Sophie PERRIN-NINKOVIC, Jennifer RIGGS, John SAPIENZA, Graziella I. SHEVLIN, Lida TEHRANI, Jingjing ZHAO
-
Patent number: 10683298Abstract: Provided herein are Heteroaryl Compounds having the following structure: wherein R1-R4 are as defined herein, compositions comprising an effective amount of a Heteroaryl Compound and methods for treating or preventing cancer, inflammatory conditions, immunological conditions, neurodegenerative diseases, diabetes, obesity, neurological disorders, age-related diseases, or cardiovascular conditions, comprising administering an effective amount of a Heteroaryl Compound to a patient in need thereof.Type: GrantFiled: November 12, 2018Date of Patent: June 16, 2020Assignee: Signal Pharmaceuticals, LLCInventors: Jan Elsner, Roy L. Harris, Branden Gingsee Lee, Deborah Mortensen, Garrick K. Packard, Patrick Papa, Jason Parnes, Sophie Perrin-Ninkovic, Jennifer Riggs, John Sapienza, Graziella I. Shevlin, Lida Tehrani, Jingjing Zhao
-
Publication number: 20190077806Abstract: Provided herein are Heteroaryl Compounds having the following structure: wherein R1-R4 are as defined herein, compositions comprising an effective amount of a Heteroaryl Compound and methods for treating or preventing cancer, inflammatory conditions, immunological conditions, neurodegenerative diseases, diabetes, obesity, neurological disorders, age-related diseases, or cardiovascular conditions, comprising administering an effective amount of a Heteroaryl Compound to a patient in need thereof.Type: ApplicationFiled: November 12, 2018Publication date: March 14, 2019Inventors: Jan ELSNER, Roy L. HARRIS, Branden Gingsee LEE, Deborah MORTENSEN, Garrick K. PACKARD, Patrick PAPA, Jason PARNES, Sophie PERRIN-NINKOVIC, Jennifer RIGGS, John SAPIENZA, Graziella I. SHEVLIN, Lida TEHRANI, Jingjing ZHAO
-
Patent number: 10167290Abstract: Provided herein are methods for the preparation of substituted pyrazino[2,3-b]pyrazines of the formula (II): the method comprising contacting a compound of formula (VI): with R1—Y in a solvent, in the presence of a palladium catalyst, wherein said contacting occurs in the presence of a base, wherein R1-R3, Y, the palladium catalyst and the base are as defined herein.Type: GrantFiled: August 18, 2017Date of Patent: January 1, 2019Assignee: Signal Pharmaceuticals, LLCInventors: Jan Elsner, Roy L. Harris, Branden Gingsee Lee, Deborah Mortensen, Garrick K. Packard, Patrick Papa, Jason Parnes, Sophie Perrin-Ninkovic, Jennifer Riggs, John Sapienza, Graziella I. Shevlin, Lida Tehrani, Jingjing Zhao
-
Publication number: 20170342080Abstract: Provided herein are Heteroaryl Compounds having the following structure: wherein R1-R4 are as defined herein, compositions comprising an effective amount of a Heteroaryl Compound and methods for treating or preventing cancer, inflammatory conditions, immunological conditions, neurodegenerative diseases, diabetes, obesity, neurological disorders, age-related diseases, or cardiovascular conditions, comprising administering an effective amount of a Heteroaryl Compound to a patient in need thereof.Type: ApplicationFiled: August 18, 2017Publication date: November 30, 2017Inventors: Jan ELSNER, Roy L. HARRIS, Branden Gingsee LEE, Deborah MORTENSEN, Garrick K. PACKARD, Patrick PAPA, Jason PARNES, Sophie PERRIN-NINKOVIC, Jennifer RIGGS, John SAPIENZA, Graziella I. SHEVLIN, Lida TEHRANI, Jingjing ZHAO
-
Patent number: 9771371Abstract: Provided herein are Heteroaryl Compounds having the following structure: wherein R1-R4 are as defined herein, compositions comprising an effective amount of a Heteroaryl Compound and methods for treating or preventing cancer, inflammatory conditions, immunological conditions, neurodegenerative diseases, diabetes, obesity, neurological disorders, age-related diseases, or cardiovascular conditions, comprising administering an effective amount of a Heteroaryl Compound to a patient in need thereof.Type: GrantFiled: October 5, 2015Date of Patent: September 26, 2017Assignee: Signal Pharmaceuticals, LLCInventors: Jan Elsner, Roy L. Harris, Branden Gingsee Lee, Deborah Mortensen, Garrick K. Packard, Patrick Papa, Jason Parnes, Sophie Perrin-Ninkovic, Jennifer Riggs, John Sapienza, Graziella I. Shevlin, Lida Tehrani, Jingjing Zhao
-
Publication number: 20160024101Abstract: Provided herein are Heteroaryl Compounds having the following structure: wherein R1-R4 are as defined herein, compositions comprising an effective amount of a Heteroaryl Compound and methods for treating or preventing cancer, inflammatory conditions, immunological conditions, neurodegenerative diseases, diabetes, obesity, neurological disorders, age-related diseases, or cardiovascular conditions, comprising administering an effective amount of a Heteroaryl Compound to a patient in need thereof.Type: ApplicationFiled: October 5, 2015Publication date: January 28, 2016Inventors: Jan ELSNER, Kimberly Elizabeth FULTZ, Roy L. HARRIS, Branden Gingsee LEE, Loui MADAKAMUTIL, Deborah MORTENSEN, Rama K. NARLA, Garrick K. PACKARD, Patrick PAPA, Jason PARNES, Sophie PERRIN-NINKOVIC, Jennifer RIGGS, Sabita SANKAR, John SAPIENZA, Graziella I. SHEVLIN, Lida TEHRANI, Weiming XU, Jingjing ZHAO
-
Patent number: 9193692Abstract: Provided herein are Heteroaryl Compounds having the following structure: wherein R1-R4 are as defined herein, compositions comprising an effective amount of a Heteroaryl Compound and methods for treating or preventing cancer, inflammatory conditions, immunological conditions, neurodegenerative diseases, diabetes, obesity, neurological disorders, age-related diseases, or cardiovascular conditions, comprising administering an effective amount of a Heteroaryl Compound to a patient in need thereof. Furthermore, provided herein are compounds having the following formulas (IV), (V), (VII) and (VIII): wherein R, R2, R3, R4, Hal and Hal2 are as defined herein, for preparation of the Heteroaryl Compounds.Type: GrantFiled: October 31, 2014Date of Patent: November 24, 2015Assignee: Signal Pharmaceuticals, LLCInventors: Sophie Perrin-Ninkovic, Roy L. Harris, John Sapienza, Graziella I. Shevlin, Patrick Papa, Branden Lee, Garrick Packard, Jingjing Zhao, Jennifer Riggs, Jason Parnes, Deborah Mortensen, Jan Elsner
-
Publication number: 20150051397Abstract: Provided herein are Heteroaryl Compounds having the following structure: wherein R1-R4 are as defined herein, compositions comprising an effective amount of a Heteroaryl Compound and methods for treating or preventing cancer, inflammatory conditions, immunological conditions, neurodegenerative diseases, diabetes, obesity, neurological disorders, age-related diseases, or cardiovascular conditions, comprising administering an effective amount of a Heteroaryl Compound to a patient in need thereof.Type: ApplicationFiled: October 31, 2014Publication date: February 19, 2015Inventors: Sophie Perrin-Ninkovic, Roy L. Harris, John Sapienza, Graziella I. Shevlin, Patrick Papa, Branden Lee, Garrick Packard, Lida Tehrani, Jingjing Zhao, Jennifer Riggs, Jason Parnes, Deborah Mortensen, Jan Elsner
-
Patent number: 8907087Abstract: Provided herein are Heteroaryl Compounds having the following structure: wherein R1-R4 are as defined herein, compositions comprising an effective amount of a Heteroaryl Compound and methods for treating or preventing cancer, inflammatory conditions, immunological conditions, neurodegenerative diseases, diabetes, obesity, neurological disorders, age-related diseases, or cardiovascular conditions, comprising administering an effective amount of a Heteroaryl Compound to a patient in need thereof.Type: GrantFiled: June 26, 2013Date of Patent: December 9, 2014Assignee: Signal Pharmaceuticals, LLCInventors: Sophie Perrin-Ninkovic, Roy L. Harris, John Sapienza, Graziella I. Shevlin, Patrick Papa, Branden Lee, Garrick Packard, Jingjing Zhao, Jennifer Riggs, Jason Parnes, Deborah Mortensen, Jan Elsner
-
Publication number: 20130289271Abstract: Provided herein are Heteroaryl Compounds having the following structure: wherein R1-R4 are as defined herein, compositions comprising an effective amount of a Heteroaryl Compound and methods for treating or preventing cancer, inflammatory conditions, immunological conditions, neurodegenerative diseases, diabetes, obesity, neurological disorders, age-related diseases, or cardiovascular conditions, comprising administering an effective amount of a Heteroaryl Compound to a patient in need thereof.Type: ApplicationFiled: June 26, 2013Publication date: October 31, 2013Applicant: SIGNAL PHARMACEUTICALS, LLCInventors: Sophie Perrin-Ninkovic, Roy L. Harris, John Sapienza, Graziella I. Shevlin, Patrick Papa, Branden Lee, Garrick Packard, Lida Tehrani, Jingjing Zhao, Jennifer Riggs, Jason Parnes, Deborah Mortensen, Weiming Xu, Loui Madakamutil, Kimberly Elizabeth Fultz, Rama Narla, Sabita Sankar, Jan Elsner
-
Patent number: 6372739Abstract: Compounds that modulate gene expression through the estrogen receptor (ER) are disclosed having the following structure, as well as pharmaceutical compositions containing the same: wherein R1, R2, R3, n and p are as defined here. Methods are also disclosed for modulating ER in cells and/or tissues expressing the same, such as bone, breast, prostate, uterus, CNS or the cardiovascular system. Methods for treating estrogen-related conditions are also disclosed, including conditions such as is breast cancer, osteoporosis, endometriosis, cardiovascular disease, hypercholesterolemia, prostatic hypertrophy, prostatic carcinomas, obesity, hot flashes, skin effects, mood swings, memory loss, and adverse reproductive effects associated with exposure to environmental chemicals or natural hormonal imbalances.Type: GrantFiled: July 2, 2001Date of Patent: April 16, 2002Assignee: Signal Pharmaceuticals, Inc.Inventors: Bernd M. Stein, David Wesley Anderson, Leah M. Gayo-Fung, Mary Doubleday, Graziella I. Shevlin, Adam Kois, Sak Khammungkhune, Ravi Kumar Jalluri, Shripad S. Bhagwat, Jeffrey A. McKie
-
Patent number: 6291456Abstract: Compounds that modulate gene expression through the estrogen receptor (ER) are disclosed having the following structure, as well as pharmaceutical compositions containing the same: wherein R1, R2, R3, n and p are as defined here. Methods are also disclosed for modulating ER in cells and/or tissues expressing the same, such as bone, breast, prostate, uterus, CNS or the cardiovascular system. Methods for treating estrogen-related conditions are also disclosed, including conditions such as is breast cancer, osteoporosis, endometriosis, cardiovascular disease, hypercholesterolemia, prostatic hypertrophy, prostatic carcinomas, obesity, hot flashes, skin effects, mood swings, memory loss, and adverse reproductive effects associated with exposure to environmental chemicals or natural hormonal imbalances.Type: GrantFiled: January 27, 2000Date of Patent: September 18, 2001Assignee: Signal Pharmaceuticals, Inc.Inventors: Bernd M. Stein, David Wesley Anderson, Leah M. Gayo-Fung, May S. Sutherland, Mary Doubleday, Graziella I. Shevlin, Adam Kois, Sak Khammungkhune, Ravi Kumar Jalluri, Shripad S. Bhagwat, Jeffrey A. McKie